GSK_Annual_Report_2021

Statutory Reports GlaxoSmithKline Pharmaceuticals Limited 76 Investors Your Company maintains regular and constructive dialogue with investors to communicate its strategy and performance in order to promote investor confidence. How your Company engages with investors ● Annual General Meeting ● Analysts’ Meet ● Detailed Company information made available online ● One-to-one meetings between institutional investors and Managing Director and Chief Financial Officer What matters ● Financial performance and commercial success ● Management of key environment, social and governance issues to mitigate risk and create opportunities What your Company is doing ● Continuing to report in line with best practice disclosure on progress towards strategic goals ● Specific business and R&D updates Health Care Professionals (HCPs) Your Company works with HCPs to understand patient needs and to ensure the HCPs understand the science behind GSK’s medicines. How your Company engages with HCPs ● Scientific dialogue to increase understanding of disease management and patient experience ● Providing high quality, balanced information about our medicines and vaccines What matters ● Access to product and scientific information ● Responsible sales and marketing practices ● Safety, efficacy and differentiated innovation What your Company is doing ● Increasing the use of digital channels to deliver a more personalised and effective sharing of information to HCPs Government and regulators Your Company works with government and regulators to advocate for policies that encourage innovation, promote efficient management of healthcare spending and give patients the support they need. How your Company engages with governments and regulators ● Meeting with regulatory bodies throughout the product introduction process to ensure high quality and safe new products ● Engaging with government health agencies to demonstrate the value of our products ● Working with government to build a strong operating environment for healthcare What matters ● Environment which values innovation and drives investment in healthcare ● Pricing of medicines ● Public health threats ● Scientific funding and collaboration What your Company is doing ● Working with policymakers to support an operating environment that remains competitive for investment, enables mobility of scientific talent and accelerates the uptake of innovative medicines ● Actively engaging on government proposals for healthcare reform ● Partnering with authorities to ensure support for global innovation, including swift regulatory approval for our pipeline products